F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comBliss GVS Pharma Ltd is a reputed Indian pharmaceutical company engaged in manufacturing and exporting a wide range of therapeutic products. Known for its focus on suppositories, topical formulations, and other dosage forms, Bliss GVS has been growing steadily, especially in international markets across Africa, Southeast Asia, and the Middle East. In this article, we will analyze Bliss GVS Pharma's stock performance and present share price targets from 2025 to 2030 based on key financial and market indicators.
Let’s explore Bliss GVS Pharma’s current market performance, shareholding pattern, and future outlook.
| Detail | Value |
|---|---|
| Current Price | ₹174.99 |
| Previous Close | ₹173.73 |
| Day's High | ₹183.19 |
| Day's Low | ₹174.00 |
| 52-Week High | ₹190.97 |
| 52-Week Low | ₹106.04 |
| All Time High | ₹221.00 |
| All Time Low | ₹18.80 |
| Market Capitalization | ₹1,899 Cr |
| VWAP | ₹178.12 |
| Beta (Volatility) | 1.29 |
| Book Value per Share | ₹95.67 |
| Face Value | ₹1 |
| Dividend Yield | 0.28% |
| 20-Day Avg Volume | 1,568,961 |
| 20-Day Avg Delivery % | 21.76% |
Bliss GVS Pharma Ltd, headquartered in Mumbai, is a prominent name in the pharmaceutical export industry. The company specializes in niche pharmaceutical segments and is a global market leader in suppository-based drug formulations.
Strong presence in over 60 countries
WHO-GMP approved manufacturing facilities
Significant focus on R&D and new product launches
Export-focused revenue model
Diversified product range including antifungals, antibiotics, and analgesics
| Investor Type | Holding (%) |
|---|---|
| Promoters | 35.44% |
| Retail & Others | 45.36% |
| Foreign Institutions | 12.65% |
| Other Domestic Institutions | 6.54% |
This shareholding structure indicates strong retail investor interest and a balanced distribution of ownership.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 165 | 185 |
| 2026 | 190 | 210 |
| 2027 | 215 | 240 |
| 2028 | 235 | 265 |
| 2029 | 260 | 285 |
| 2030 | 280 | 315 |
These targets are based on Bliss GVS’s growth trajectory, export expansion, EPS growth, and macroeconomic conditions.
By the end of 2025, Bliss GVS Pharma is likely to benefit from higher export demand, especially in African and Middle Eastern markets.
Why?
Continued demand for antifungal and antibiotic drugs
Healthy revenue stream from existing long-term contracts
Better operating margins compared to industry average
Investment Advice: Ideal for long-term investors who are seeking undervalued pharma stocks with growth potential.
In 2026, the stock is expected to show moderate growth backed by new product introductions and deeper global market penetration.
Why?
Entry into newer therapeutic categories
Better cash flows and low debt levels
Expanding footprint in Latin America
Investment Advice: Consider holding or accumulating during price dips; strong fundamentals make this stock a low-risk pharma bet.
As Bliss GVS leverages its R&D capabilities, 2027 could witness a sharp jump in earnings and valuation multiples.
Why?
Higher capacity utilization of manufacturing units
Increase in patent filings and approvals
Product launches in regulated markets
Investment Advice: Long-term investors can benefit from price appreciation; review Q2 and Q3 earnings for strategic decisions.
The company is expected to hit its stride by 2028 with enhanced operational efficiency and brand recognition overseas.
Why?
Consistent rise in export revenue
Technological innovation in drug delivery systems
Potential merger or acquisition opportunities
Investment Advice: Add during consolidation phases. Maintain a diversified pharma portfolio including Bliss GVS.
Bliss GVS Pharma is likely to emerge as a mid-cap pharma leader with strong growth prospects.
Why?
Diversified revenue sources
Higher Return on Equity (RoE)
Expansion into hospital and institutional segments
Investment Advice: Continue to hold for long-term compounding. Dividend yield may increase with profit growth.
By 2030, Bliss GVS may achieve multi-fold growth if it maintains current growth momentum and execution capability.
Why?
Strategic global tie-ups and distribution deals
Consistent profitability with expanding margins
Strong management with international experience
Investment Advice: Excellent stock for long-term wealth creation. Reinvest dividends and monitor regulatory developments.
Yes, if you're looking for a stable pharma company with consistent exports, expanding product lines, and rising profitability. Bliss GVS Pharma combines innovation with execution, making it a reliable stock in the healthcare sector.
Strong export-led business model
Niche leadership in suppository drug forms
Consistent earnings and low debt
Potential for PE re-rating
Overdependence on exports
Regulatory challenges in international markets
Currency fluctuation risks due to dollar-based revenues
High retail ownership could lead to short-term volatility
Bliss GVS Pharma Ltd is steadily making its mark in the Indian and global pharmaceutical landscape. With its specialized focus, global distribution, and commitment to R&D, the company is poised for long-term success. Currently trading around ₹174.99, analysts project that the share could reach up to ₹315 by 2030.
For investors seeking stable returns, moderate risk, and a sector with growing global demand, Bliss GVS Pharma can be a smart portfolio addition. Always consult a financial advisor before making investment decisions.
What is the current price of Bliss GVS Pharma stock?
As of August 1, 2025, the price is around ₹174.99.
Is Bliss GVS Pharma a good long-term investment?
Yes, due to its strong export model, R&D focus, and consistent profitability.
What are the risks in investing in Bliss GVS Pharma?
Currency fluctuations, regulatory changes, and global market dependencies.
What is the shareholding pattern of Bliss GVS Pharma?
Promoters: 35.44%, Retail & Others: 45.36%, FIIs: 12.65%, DIIs: 6.54%.
What is the target price of Bliss GVS Pharma in 2030?
Analysts predict a target range of ₹280 to ₹315 by 2030.
Disclaimer: This blog is for educational and informational purposes only. Please consult a SEBI-registered financial advisor before making any investment decisions.
Register & Login